logo
Plus   Neg
Share
Email

Rotork: FY Adj. Operating Profit To Be In-line With Guidance On OCC Basis

Rotork Plc (ROR.L) issued a trading update covering the four months to 27 October 2019. Order intake improved from a year ago, on an organic constant currency basis, and was also ahead on a year-to-date basis. The Group remains highly cash generative with a strong balance sheet.

For 2019, Rotork projects reported adjusted operating profit to be in-line with management expectations on an organic constant currency basis. Full year adjusted operating margins are expected to show good progress year-on-year.

The Group now expects modestly lower organic constant currency sales year-on-year in 2019. A slightly greater than usual proportion of recent orders are not for delivery until next year, the Group noted.

Rotork Plc will publish its full-year results on 3 March 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT